Next Article in Journal
Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
Next Article in Special Issue
Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice
Previous Article in Journal
Comparative Studies of the Uptake and Internalization Pathways of Different Lipid Nano-Systems Intended for Brain Delivery
Previous Article in Special Issue
Dendrimers in Corneal Drug Delivery: Recent Developments and Translational Opportunities
 
 
Article
Peer-Review Record

Lysine-Dendrimer, a New Non-Aggressive Solution to Rebalance the Microbiota of Acne-Prone Skin

Pharmaceutics 2023, 15(8), 2083; https://doi.org/10.3390/pharmaceutics15082083
by Julie Leignadier 1,*,†, Marie Drago 2,†, Olivier Lesouhaitier 3, Magalie Barreau 3, Albert Dashi 4, Oliver Worsley 4 and Joan Attia-Vigneau 1
Reviewer 1: Anonymous
Reviewer 2:
Pharmaceutics 2023, 15(8), 2083; https://doi.org/10.3390/pharmaceutics15082083
Submission received: 27 June 2023 / Revised: 18 July 2023 / Accepted: 1 August 2023 / Published: 3 August 2023
(This article belongs to the Special Issue Applications of Dendrimers in Biomedicine)

Round 1

Reviewer 1 Report

The article is very interesting and well written

The material and methods section explains the methods used very well, the figures are of a good standard. I would have just minor revisions for the authors

1) Add a paragraph where they talk about the limitations of the study in order to allow for more discussion in the future

2) In the introduction we need to discuss the role of the microbiota in general, its importance is of great importance these years not only in acne but also in other related diseases such as HS. I leave a reference that the authors can use

- DOI: 10.1111/ced.15291

3) The discussion and conclusion section should be divided.

4) Minimal language revision is required

Minor editing of English language required

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Great work! Please provide some minor changes in methodology part in order to explain first 3 comments. I am interested to read the answer to 4th comment.

Comment 1: Why in clinical study with G2-dendrimers for the control placebo cream (without G2-dendrimers) was not used?

Comment 2: Explain methodology „dermatologist counted non-inflamatory lesions“ in more detail.

Comment 3: Explain why 100% Squalene was used in first 4 days in clinical study with G2-dendrimers in full formulation.

Comment 4: Do you have any data for any clinical studies with placebo formulation?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop